NCT06252649 2026-04-02
CodeBreaK 301
Amgen
Phase 3 Recruiting
Clinical Trials
18 trialsNCT05863195 2026-03-23
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05198934 2026-02-06
CodeBreak300
Amgen
Phase 3 Active not recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT02162563 2025-02-06
CAIRO5
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT03635021 2024-10-21
CR-SEQUENCE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 3 Active not recruiting
NCT06509126 2024-07-19
IMPROVE-2
National Cancer Institute, Naples
Phase 3 Recruiting
NCT06226857 2024-01-29
CRC01
City Clinical Oncology Hospital No 1
Phase 3 Recruiting
NCT02394795 2023-11-01
PARADIGM
Takeda
Phase 3 Completed
NCT03231722 2023-01-05
TRIPLETE
Gruppo Oncologico del Nord-Ovest
Phase 3 Completed
NCT00113763 2022-11-07
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00364013 2022-11-07
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Amgen
Phase 3 Completed
NCT00339183 2022-09-23
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
Amgen
Phase 3 Completed
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00389870 2022-06-01
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
University of Leeds
Phase 3 Completed
NCT03300609 2020-06-11
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
University of Southern California
Phase 3 Terminated
NCT00115765 2018-10-17
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Amgen
Phase 3 Completed
NCT01412957 2017-03-15
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed